Terns Pharmaceuticals, Inc. (TERN) Earnings History
Net Loss8 years of earnings data (2018–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Terns Pharmaceuticals, Inc. (TERN) Earnings Overview
As of June 22, 2026, Terns Pharmaceuticals, Inc. (TERN) reported trailing twelve-month net income of -$96M, reflecting +8.0% year-over-year growth. The company earned $-1.03 per diluted share over the past four quarters.
Looking at the long-term picture, TERN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$18M in fiscal 2018.
Terns Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDGL (-$309M net income, -30.1% margin), AKRO (-$293M net income), HIMS (-$13M net income, 5.5% margin), TERN has comparable earnings metrics. Compare TERN vs MDGL →
TERN Earnings vs Peers
Earnings metrics vs comparable public companies
TERN Historical Earnings Data (2018–2025)
8 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$96M | -8.3% | -$110M | $-1.03 | - | - |
| 2024 | -$89M | +1.5% | -$102M | $-1.12 | - | - |
| 2023 | -$90M | -49.5% | -$103M | $-1.27 | - | - |
| 2022 | -$60M | -20.3% | -$62M | $-1.67 | - | - |
| 2021 | -$50M | -70.9% | -$50M | $-1.98 | -5015.8% | -4986.0% |
| 2020 | -$29M | +57.3% | -$37M | $-1.61 | - | - |
| 2019 | -$69M | -288.6% | -$70M | $-2.74 | - | - |
| 2018 | -$18M | - | -$18M | $-0.74 | - | - |
Download Data
Export TERN earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
8+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
TERN — Frequently Asked Questions
Quick answers to the most common questions about buying TERN stock.
What is TERN earnings per share (EPS)?
TERN trailing twelve-month (TTM) diluted EPS is $-1.03, reflecting +8.0% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2018 to 2025 is available in the table on this page.
What is Terns Pharmaceuticals, Inc.'s net income?
Terns Pharmaceuticals, Inc. (TERN) trailing twelve-month net income is $-96M as of 2025. Earnings grew +8.0% year-over-year.
Is TERN profitable?
TERN is not currently profitable on a TTM basis, reporting a net loss of $-96M. Net margin is N/A. Investors should monitor for a return to profitability.
What is TERN's earnings growth rate?
TERN compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2018 to 2025.
What are TERN's profit margins?
Terns Pharmaceuticals, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -14.2%.
Is TERN growing earnings?
TERN is growing earnings steadily. YoY EPS growth of +8.0% is consistent with the 5-year CAGR of N/A. TTM net income is $-96M.
What was TERN's best earnings year?
Terns Pharmaceuticals, Inc.'s highest annual net income on record is $-18M, achieved in fiscal year 2018. Earnings history on this page spans 2018 to 2025 and includes all annual and quarterly figures.
What were TERN's earnings last quarter?
TERN's most recent reported quarter was Q4 2025. Net income was $-24M with diluted EPS of $-0.24. For a full breakdown of all quarters, see the quarterly earnings table on this page.